Fornebu, September 11, 2026 - Reference is made to the planned merger between
Aker BioMarine ASA ("Aker BioMarine") and Aker Capital NewCo AS ("MergerCo"),
an indirect wholly-owned subsidiary of Aker ASA ("Aker") announced on July 16,
2026 and approved by an extraordinary general meeting of Aker BioMarine on
August 17, 2026 (the "Merger").
As a preparatory step for completion of the Merger, Aker Capital AS ("Aker
Capital"), a wholly-owned subsidiary of Aker, has today transferred all of its
69,065,940 shares in Aker BioMarine, equal to approximately 78.73% of the
shares and votes in Aker BioMarine, to its wholly-owned subsidiary MergerCo.
Finanstilsynet (the Financial Supervisory Authority of Norway) has pursuant to
section 6-2 (3) of the Norwegian Securities Trading Act granted an exemption
from the mandatory offer obligation for the transfer.
With effect from the third quarter of 2026, Aker BioMarine will be included in
Aker ASA's Net Asset Value (NAV) as an unlisted investment, based on the
merger valuation of NOK 105 per share. This implies a value of NOK
7,251,923,700 for Aker's current 78.73% ownership interest and NOK
9,210,970,230 on a 100% basis upon completion of the merger.
-ENDS-
This information has been submitted pursuant to section 5-12 of the Norwegian
Securities Trading Act.
Investor contact:
Fredrik Berge, Head of Investor Relations
+47 45 03 20 90
fredrik.berge@akerasa.com
ations\
+47 45 03 20 90\
fredrik.berge@akerasa.com\